
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 1374853-91-4 |
| Catalog No. | 2A-0202209 |
| Chinese Name | Pembrolizumab |
| Synonyms | LAMBROLIZUMAB |
| Molecular Formula | C85H170N4OS |
| Molecular Weight | 1296.4 |
| Storage Condition | -20℃, avoid light |
| Application | Pembrolizumab is a humanized antibody, an inhibitor of PD-1, used in cancer immunity research. |
| PubChem ID | 474379191 |
| SMILES | C=CCCCCN(CC(C)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC.CC.CCCCC=CC=CCCCCCCC(C)CN(CCCS)CC(C)CCCCCC=CC=CCCCCC.CCCCN1CCN(CCC)CC1 |
| InChI | InChI=1S/C37H69NS.C35H71NO.C11H24N2.C2H6/c1-5-7-9-11-13-15-17-19-21-23-25-27-30-36(3)34-38(32-29-33-39)35-37(4)31-28-26-24-22-20-18-16-14-12-10-8-6-2;1-5-8-11-14-16-18-20-22-24-26-29-34(4)32-36(31-28-13-10-7-3)33-35(37)30-27-25-23-21-19-17-15-12-9-6-2;1-3-5-7-13-10-8-12(6-4-2)9-11-13;1-2/h11,13-18,20,36-37,39H,5-10,12,19,21-35H2,1-4H3;7,34-35,37H,3,5-6,8-33H2,1-2,4H3;3-11H2,1-2H3;1-2H3/b13-11+,16-14+,17-15+,20-18+;;; |
| InChI Key | AMOIBCKFWIUEKF-NAMKDLAHSA-N |
| Transport Info | Product Name: Pembrolizumab (anti-PD-1) |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Adalimumab | 331731-18-1 | 2A-0202027 |
| Alirocumab | 1245916-14-6 | 2A-2181927 |
| Denosumab (usan) | 615258-40-7 | 2A-0202030 |
| Eculizumab | 219685-50-4 | 2A-2181929 |
| Evolocumab | 1256937-27-5 | 2A-2181930 |
| Ramucirumab | 947687-13-0 | 2A-0202035 |
| Secukinumab | 875356-43-7 | 2A-2181935 |
| Vedolizumab | 943609-66-3 | 2A-2181936 |
| Alemtuzumab | 216503-57-0 | 2A-2181937 |
| Efmoroctocog alfa | 1270012-79-7 | 2A-2181938 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA